← 返回前沿论文

通过 ProMisE 分型理解空间免疫表型对子宫内膜癌患者生存的影响

英文原题:Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification.

PubMed 2025/01/03(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

研究概要

不仅评估分子分型,还评估免疫表型,可能有助于在EC中实现更个性化的免疫治疗,而阐明三种免疫表型形成背后的机制,可能有助于发现新的免疫治疗靶点。

中文摘要

目的:本研究聚焦基于CD8阳性TIL(肿瘤浸润淋巴细胞)分布的免疫表型,与子宫内膜癌(EC)分子亚型及患者预后的关系。 患者与方法:研究分析两个EC患者队列,共145人,并采用子宫内膜癌分子风险分类器(ProMisE)分为POLE突变型(POLEmut)、错配修复缺陷型(MMRd)、无特定分子谱型(NSMP)和p53异常型(p53abn)。通过免疫组化染色和先进图像分析软件,检测肿瘤中心及浸润边缘的CD8阳性TIL。研究评估这些免疫表型与分子亚型及患者生存的相关性,并采用RNA测序探索影响免疫表型的肿瘤来源因素。 结果:根据CD8阳性TIL分布,EC患者可分为炎症型、排斥型和荒漠型三种免疫表型。炎症型最常见于POLEmut和MMRd亚型;荒漠型则主要见于NSMP亚型,但也观察到其他免疫表型。所有p53abn亚型均表现为非炎症型(排斥型或荒漠型)。非炎症型患者预后明显差于炎症型患者。RNA测序分析显示,在MMRd和NSMP亚型的非炎症表型中,MYC靶基因和I型干扰素应答基因表达分别富集。 结论:除分子分型外,同时评估免疫表型可能有助于为EC患者制定更个体化的免疫治疗方案;阐明三种免疫表型形成的机制也可能发现新的免疫治疗靶点。

展开英文摘要原文

OBJECTIVES: We focused on how the immunophenotypes based on the distribution of CD8-positive tumor-infiltrating lymphocytes (TILs) relate to the endometrial cancer (EC) molecular subtypes and patients' prognosis. PATIENTS AND METHODS: Two cohorts of EC patients (total n = 145) were analyzed and categorized using the Molecular Risk Classifier for Endometrial cancer (ProMisE): POLEmut (POLE mutation), MMRd (mismatch repair deficiency), NSMP (no specific molecular profile), and p53abn (p53 abnormality). CD8-positive TILs, within the central tumor and the invasive margin, were examined by using immunohistochemical staining and advanced image-analysis software. It was investigated whether these immunophenotypes correlate with the molecular subtypes and patients' survival. RNA-sequencing (RNA-seq) was used to explore tumor-derived factors influencing these immunophenotypes. RESULTS: Three distinct immunophenotypes (inflamed, excluded, and desert) based on the CD8-positive TIL patterns were identified in EC patients. Notably, the inflamed phenotype was most frequently observed in the POLEmut and MMRd subtypes, while the desert phenotype was predominant in the NSMP subtype; however, other immunophenotypes were also observed. All p53abn subtype showed the non-inflamed (excluded or desert) phenotype. The prognosis was markedly poorer in the patients with the non-inflamed phenotype than in those with the inflamed phenotype. The RNA-seq analysis showed that the expression of MYC target genes and type-1 interferon response genes was enriched in the non-inflamed phenotype in MMRd and NSMP subtypes, respectively. CONCLUSION: Evaluating not only the molecular classification but also the immunophenotype may lead to more personalized immunotherapy in EC and elucidating the mechanisms that underlie the formation of the three immunophenotypes could lead to the discovery of new immunotherapy targets.

论文信息

作者
Hattori S、Yoshikawa N、Liu W、Matsukawa T、Kubokawa M、Yoshida K、Yoshihara M、Tamauchi S
第一作者单位
Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, 65, Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8560, Japan.Japan
通讯作者单位
Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, 65, Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8560, Japan. n-yoshikawa@med.nagoya-u.ac.jp.Japan
期刊
Cancer immunology, immunotherapy : CII2025 Jan 3
原文标识
PubMed 39751650 · DOI 10.1007/s00262-024-03919-8